非裔美国人和非洲-加勒比人群化疗引起的心肌病的发病率及相关危险因素

Mohammed Al-Sadawi, Kurnvir Singh, Violeta Capric, Amena Mohiuddin, Michael Haddadin, Arismendy Nunez, Shakil Shaikh, Inna Bukharovich, Samy I McFarlane
{"title":"非裔美国人和非洲-加勒比人群化疗引起的心肌病的发病率及相关危险因素","authors":"Mohammed Al-Sadawi,&nbsp;Kurnvir Singh,&nbsp;Violeta Capric,&nbsp;Amena Mohiuddin,&nbsp;Michael Haddadin,&nbsp;Arismendy Nunez,&nbsp;Shakil Shaikh,&nbsp;Inna Bukharovich,&nbsp;Samy I McFarlane","doi":"10.15344/2456-8007/2020/154","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced cardiomyopathy (CICM) and heart failure are major complications of cancer therapeutics and can result in significant morbidity and mortality. There is limited data on the incidence and risk factors of CICM in African American and Afro-Caribbean patients.</p><p><strong>Methods: </strong>We performed a retrospective chart review to evaluate the baseline characteristics that may predispose to CICM. Patients were African American and Afro-Caribbean ethnicity. Data was collected between 2014 to 2018. Patients had transthoracic echocardiogram (TTE) or multigated acquisition scan (MUGA) prior to cancer therapy and every 3 months thereafter, until the end of the regimen. CICM was defined as a ≥16% reduction in LVEF or ≥10% reduction in LVEF to a value <50%.</p><p><strong>Results: </strong>A total of 230 patients were studied, with a mean age of 54±12 years with 91% were females, BMI 30±4, 81% were taking anthracyclines, 87% were on Trastuzumab while 5% were receiving both medications. The prevalence of comorbidities was as follows: hypertension 8%, diabetes mellitus 8%, ESRD 8%, dyslipidemia 8%, CAD 7%. The incidence of CICM was 7% overall, while it was 6% and 8% for patients taking Anthracyclines and Trastuzumab, respectively. CICM was associated with dyslipidemia (r= .22, p= .001), hypertension (r= .12, p= .05), baseline ejection fraction (r= -.21, p= .001) and concomitant use of radiation therapy (r= .147, p= .02), but not with age, gender, beta blocker use, angiotensin converting enzyme inhibitor use, number of chemotherapy cycles or stage of the malignancy. On multivariate analysis CICM was independently associated with baseline ejection fraction (β= -.193, P= .003) and dyslipidemia (β= -.20, P= .003).</p><p><strong>Conclusion: </strong>The incidence of CICM in African Americans and Afro-Caribbean is higher than reported in the general population. Dyslipidemia and baseline ejection fraction were seen as the major risk factors associated with the higher incidence of CICM.</p>","PeriodicalId":73437,"journal":{"name":"International journal of clinical research & trials","volume":"5 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations.\",\"authors\":\"Mohammed Al-Sadawi,&nbsp;Kurnvir Singh,&nbsp;Violeta Capric,&nbsp;Amena Mohiuddin,&nbsp;Michael Haddadin,&nbsp;Arismendy Nunez,&nbsp;Shakil Shaikh,&nbsp;Inna Bukharovich,&nbsp;Samy I McFarlane\",\"doi\":\"10.15344/2456-8007/2020/154\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chemotherapy-induced cardiomyopathy (CICM) and heart failure are major complications of cancer therapeutics and can result in significant morbidity and mortality. There is limited data on the incidence and risk factors of CICM in African American and Afro-Caribbean patients.</p><p><strong>Methods: </strong>We performed a retrospective chart review to evaluate the baseline characteristics that may predispose to CICM. Patients were African American and Afro-Caribbean ethnicity. Data was collected between 2014 to 2018. Patients had transthoracic echocardiogram (TTE) or multigated acquisition scan (MUGA) prior to cancer therapy and every 3 months thereafter, until the end of the regimen. CICM was defined as a ≥16% reduction in LVEF or ≥10% reduction in LVEF to a value <50%.</p><p><strong>Results: </strong>A total of 230 patients were studied, with a mean age of 54±12 years with 91% were females, BMI 30±4, 81% were taking anthracyclines, 87% were on Trastuzumab while 5% were receiving both medications. The prevalence of comorbidities was as follows: hypertension 8%, diabetes mellitus 8%, ESRD 8%, dyslipidemia 8%, CAD 7%. The incidence of CICM was 7% overall, while it was 6% and 8% for patients taking Anthracyclines and Trastuzumab, respectively. CICM was associated with dyslipidemia (r= .22, p= .001), hypertension (r= .12, p= .05), baseline ejection fraction (r= -.21, p= .001) and concomitant use of radiation therapy (r= .147, p= .02), but not with age, gender, beta blocker use, angiotensin converting enzyme inhibitor use, number of chemotherapy cycles or stage of the malignancy. On multivariate analysis CICM was independently associated with baseline ejection fraction (β= -.193, P= .003) and dyslipidemia (β= -.20, P= .003).</p><p><strong>Conclusion: </strong>The incidence of CICM in African Americans and Afro-Caribbean is higher than reported in the general population. Dyslipidemia and baseline ejection fraction were seen as the major risk factors associated with the higher incidence of CICM.</p>\",\"PeriodicalId\":73437,\"journal\":{\"name\":\"International journal of clinical research & trials\",\"volume\":\"5 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of clinical research & trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15344/2456-8007/2020/154\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical research & trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15344/2456-8007/2020/154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

背景:化疗引起的心肌病(CICM)和心力衰竭是癌症治疗的主要并发症,可导致显著的发病率和死亡率。关于非裔美国人和非裔加勒比患者CICM的发生率和危险因素的数据有限。方法:我们进行了回顾性的图表回顾,以评估可能易患CICM的基线特征。患者为非裔美国人和非裔加勒比人。数据收集于2014年至2018年。患者在癌症治疗前进行经胸超声心动图(TTE)或多通道采集扫描(MUGA),此后每3个月进行一次,直到治疗结束。CICM被定义为LVEF降低≥16%或LVEF降低≥10%达到一定值。结果:共研究了230例患者,平均年龄为54±12岁,其中91%为女性,BMI为30±4,81%服用蒽环类药物,87%服用曲妥珠单抗,5%同时服用两种药物。合并症患病率如下:高血压8%,糖尿病8%,ESRD 8%,血脂异常8%,CAD 7%。总的来说,CICM的发生率为7%,而服用蒽环类药物和曲妥珠单抗的患者分别为6%和8%。CICM与血脂异常(r= 0.22, p= 0.001)、高血压(r= 0.12, p= 0.05)、基线射血分数(r= -)相关。21, p= .001)和同时使用放射治疗(r= .147, p= .02),但与年龄、性别、受体阻滞剂使用、血管紧张素转换酶抑制剂使用、化疗周期数或恶性肿瘤分期无关。在多变量分析中,CICM与基线射血分数独立相关(β= -)。193, P= .003)和血脂异常(β= .003)。20, p = .003)。结论:非裔美国人和非裔加勒比人的CICM发病率高于一般人群。血脂异常和基线射血分数被认为是与CICM高发生率相关的主要危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations.

Background: Chemotherapy-induced cardiomyopathy (CICM) and heart failure are major complications of cancer therapeutics and can result in significant morbidity and mortality. There is limited data on the incidence and risk factors of CICM in African American and Afro-Caribbean patients.

Methods: We performed a retrospective chart review to evaluate the baseline characteristics that may predispose to CICM. Patients were African American and Afro-Caribbean ethnicity. Data was collected between 2014 to 2018. Patients had transthoracic echocardiogram (TTE) or multigated acquisition scan (MUGA) prior to cancer therapy and every 3 months thereafter, until the end of the regimen. CICM was defined as a ≥16% reduction in LVEF or ≥10% reduction in LVEF to a value <50%.

Results: A total of 230 patients were studied, with a mean age of 54±12 years with 91% were females, BMI 30±4, 81% were taking anthracyclines, 87% were on Trastuzumab while 5% were receiving both medications. The prevalence of comorbidities was as follows: hypertension 8%, diabetes mellitus 8%, ESRD 8%, dyslipidemia 8%, CAD 7%. The incidence of CICM was 7% overall, while it was 6% and 8% for patients taking Anthracyclines and Trastuzumab, respectively. CICM was associated with dyslipidemia (r= .22, p= .001), hypertension (r= .12, p= .05), baseline ejection fraction (r= -.21, p= .001) and concomitant use of radiation therapy (r= .147, p= .02), but not with age, gender, beta blocker use, angiotensin converting enzyme inhibitor use, number of chemotherapy cycles or stage of the malignancy. On multivariate analysis CICM was independently associated with baseline ejection fraction (β= -.193, P= .003) and dyslipidemia (β= -.20, P= .003).

Conclusion: The incidence of CICM in African Americans and Afro-Caribbean is higher than reported in the general population. Dyslipidemia and baseline ejection fraction were seen as the major risk factors associated with the higher incidence of CICM.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信